Sentence examples for moderate hepatic dysfunction from inspiring English sources

On the basis on these data, a dose reduction of ATV is advised for patients with moderate hepatic dysfunction.

Indeed, Twelves et al (1999) demonstrated that mild to moderate hepatic dysfunction has no clinically significant influence on the pharmacokinetic parameters of capecitabine and its metabolites.

According to the prescribing information summary, dose adjustments are required for patients with mild to moderate hepatic dysfunction (Child-Pugh class A and B).

Instead, it is slowly excreted, unchanged, in both urine and the feces (terminal half-life = 393 ± 73.5 h), which means that no dosage adjustment is required for age, or for renal or mild to moderate hepatic dysfunction.

Long-term toxicity including mild to moderate hepatic dysfunction(17/55), abdominal pain and diarrhea(15/55), transient albuminuria(2/55) and Mild elevation of blood urea nitrogen and creatinine(1/55) was observed in this cohort.

Mild to moderate hepatic dysfunction had no significant influence on the pharmacokinetics of capecitabine and its metabolites (Twelves et al, 1999), whereas food had a profound effect on the area under the concentration – time curve (AUC) of capecitabine (Reigner et al, 1998).

The presence of mild-to-moderate hepatic dysfunction had no clinically significant effect on the pharmacokinetics of capecitabine and its metabolites [ 15].

Dosage adjustment of tamsulosin is not necessary in patients with mild-to-severe renal impairment (CLcr ≥ 10 mL/min/1.73 m) or mild-to-moderate hepatic dysfunction (Child-Pugh's classification A and B).

Peak plasma concentrations of oxycodone and noroxycodone are higher in patients with mild-to-moderate hepatic dysfunction or mild-to-severe renal dysfunction, and oxymorphone concentrations are lower in patients with impaired hepatic function [ 36– 36].

The main finding was that mild-to-moderate hepatic dysfunction, assessed by serial measurements of liver enzyme levels, was apparent in almost all dengue patients and correlated with other measures of severity, although the most abnormal results were noted rather later than during the generally accepted critical period for other complications.

Though concerns have been raised about the potential hepatotoxicity of MIC due to tumor formation in rodents, CFG is the only EC for which dosage adjustment is recommended for patients with moderate to severe hepatic dysfunction.